We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal

Download Mobile App





Slight Variability in Coronavirus Mutations Could Make COVID-19 Vaccine Effective Against All SARS-CoV-2 Strains

By HospiMedica International staff writers
Posted on 05 Aug 2020
Print article
Illustration
Illustration
Researchers have found that the SARS-CoV-2 virus, which presents at least six strains, shows little variability despite its mutations, suggesting that the mutations do not impinge on the process of developing effective COVID-19 vaccines.

Currently, there are six strains of coronavirus. The original one is the L strain that appeared in Wuhan in December 2019. Its first mutation - the S strain - appeared at the beginning of 2020, while, since mid-January 2020, there were the V and G strains. To date, strain G is the most widespread and mutated into strains GR and GH at the end of February 2020. A look at the coronavirus map shows that strains G and GR are the most frequent across Europe and Italy. According to the available data, GH strain seems close to non-existence in Italy, while it occurs more frequently in France and Germany. In North America the most widespread strain is GH, while the GR strain is found more frequently in South America. In Asia, where the Wuhan L strain initially appeared, the spread of strains G, GH and GR is increasing. These strains landed in Asia only at the beginning of March, more than a month after their spread in Europe. Globally, strains G, GH and GR are constantly increasing. Strain S can be found in some restricted areas in the US and Spain. The L and V strains are gradually disappearing. In addition to the six main coronavirus strains, researchers have also identified some infrequent mutations, which, at the moment, are not worrying but still need to be monitored.

Researchers at the University of Bologna (Bologna, Italy) carried out the most extensive study ever on SARS-CoV-2 sequencing by drawing from the analysis of 48,635 coronavirus genomes, which were isolated by researchers in labs all over the world. This made it possible for the researchers to map the spread and the mutations of the virus during its journey to all continents. The first results were encouraging as they found that the coronavirus presents little variability, approximately seven mutations per sample.

"The SARS-CoV-2 coronavirus is presumably already optimized to affect human beings, and this explains its low evolutionary change", said Federico Giorgi, researcher at Unibo and coordinator of the study. "This means that the treatments we are developing, including a vaccine, might be effective against all the virus strains".

Related Links:
University of Bologna

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
EMG Software
Natus Elite

Print article

Channels

Critical Care

view channel
Image: Peerbridge Cor is a 3-lead, 2-channel wireless AECG that simplifies the testing and diagnostic process (Photo courtesy of Peerbridge Health)

First-of-its-Kind Trial to Measure Ejection Fraction Severity Directly from AI-Enabled Remote ECG Wearable

Echocardiograms are a standard diagnostic tool to measure ejection fraction but require a clinical setting for administration. This can pose challenges such as scheduling delays, staffing shortages, accessibility... Read more

Surgical Techniques

view channel
Image: Fixation screws for ligament to bone repair (Photo courtesy of 4D Medicine)

Novel Biomaterial Platform Opens Up New Possibilities for Implants and Devices

Resorbable biomaterials, crucial for implantable medical devices, have seen little innovation over decades. Materials like Polylactic Acid (PLA), Polycaprolactone (PCL), and Poly Lactic-co-Glycolic Acid... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more

Business

view channel
Image: The Innovalve transseptal delivery system is designed to enable safe deployment of the Innovalve implant (Photo courtesy of Innovalve Bio)

Edwards Lifesciences Acquires Sheba Medical’s Innovalve Bio Medical

Edwards Lifesciences (Irvine, CA, USA), a leading company in medical innovations for structural heart disease and critical care, has acquired Innovalve Bio Medical LTD. (Ramat Gan, Israel), an early-stage... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.